Endocrine Signalling Group, Royal Veterinary College, University of London, Royal College Street, London NW1 0TU, UK.
Comparative Biomedical Sciences, Royal Veterinary College, University of London, Royal College Street, London NW1 0TU, UK.
Int J Mol Sci. 2021 Jan 22;22(3):1076. doi: 10.3390/ijms22031076.
Patients harbouring mutations in genes encoding C-type natriuretic peptide (CNP; ) or its receptor guanylyl cyclase B (GC-B, ) suffer from severe growth phenotypes; loss-of-function mutations cause achondroplasia, whereas gain-of-function mutations cause skeletal overgrowth. Although most of the effects of CNP/GC-B on growth are mediated directly on bone, evidence suggests the natriuretic peptides may also affect anterior pituitary control of growth. Our previous studies described the expression of and in a range of human pituitary tumours, normal human pituitary, and normal fetal human pituitary. However, the natriuretic peptide system in somatotropes has not been extensively explored. Here, we examine the expression and function of the CNP/GC-B system in rat GH3 somatolactotrope cell line and pituitary tumours from a cohort of feline hypersomatotropism (HST; acromegaly) patients. Using multiplex RT-qPCR, all three natriuretic peptides and their receptors were detected in GH3 cells. The expression of was significantly enhanced following treatment with either 100 nM TRH or 10 µM forskolin, yet only expression was sensitive to forskolin stimulation; the effects of forskolin and TRH on expression were PKA- and MAPK-dependent, respectively. CNP stimulation of GH3 somatolactotropes significantly inhibited and expression, but dramatically enhanced expression at the same time point. Oestrogen treatment significantly enhanced expression of and in GH3 somatolactotropes, but inhibited CNP-stimulated cGMP accumulation. Finally, transcripts for all three natriuretic peptides and receptors were expressed in feline pituitary tumours from patients with HST. expression was negatively correlated with pituitary tumour volume and expression, but positively correlated with and expression. Collectively, these data provide mechanisms that control expression and function of CNP in somatolactotrope cells, and identify putative transcriptional targets for CNP action in somatotropes.
患有编码 C 型利钠肽(CNP;)或其受体鸟苷酸环化酶 B(GC-B,)基因突变的患者表现出严重的生长表型;功能丧失性突变导致软骨发育不全,而获得性功能突变导致骨骼过度生长。尽管 CNP/GC-B 对生长的大多数影响是直接在骨骼上介导的,但有证据表明利钠肽也可能影响垂体前叶对生长的控制。我们之前的研究描述了一系列人类垂体肿瘤、正常人类垂体和正常胎儿人类垂体中 和 的表达。然而,利钠肽系统在生长激素细胞中的研究还不够广泛。在这里,我们研究了 CNP/GC-B 系统在大鼠 GH3 生长激素细胞和猫群中一组高生长激素血症(HST;肢端肥大症)患者的垂体肿瘤中的表达和功能。使用多重 RT-qPCR,在 GH3 细胞中检测到所有三种利钠肽及其受体。用 100 nM TRH 或 10 µM forskolin 处理后, 表达显著增强,但只有 表达对 forskolin 刺激敏感; forskolin 和 TRH 对 表达的影响分别依赖于 PKA 和 MAPK。CNP 刺激 GH3 生长激素细胞显著抑制 和 表达,但同时显著增强 表达。雌激素处理显著增强 GH3 生长激素细胞中 和 表达,但抑制 CNP 刺激的 cGMP 积累。最后,三种利钠肽及其受体的转录本在患有 HST 的猫垂体肿瘤中表达。 表达与垂体肿瘤体积和 表达呈负相关,但与 和 表达呈正相关。总之,这些数据提供了控制 CNP 在生长激素细胞中表达和功能的机制,并确定了 CNP 在生长激素细胞中作用的潜在转录靶点。